Acumen Pharmaceuticals, Inc. (ABOS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ABOS currently has 72.2M outstanding shares. with significant dilution risk as 53.3M authorized shares could dilute existing holders by 73.8%. The company has diluted shareholders by 20.15% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 26, 2026 |
10-K filing | 72.2M shares outstanding |
72M | 53M |
| Mar 16, 2026 |
8-K filing: Acumen Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to sell 10,833,331 shares of common stock at $3.30 per share in a private placement, with gross proceeds expected to be approximately $35.75 million. ($35.75M proceeds) |
61M | 53M |
| Nov 12, 2025 |
10-Q filing | 60.6M shares outstanding |
61M | 53M |
| Aug 12, 2025 |
10-Q filing | 60.6M shares outstanding |
61M | 53M |
| May 13, 2025 |
10-Q filing | 60.5M shares outstanding |
61M | 53M |
| Mar 27, 2025 |
10-K filing | 60.0M shares outstanding |
60M | 53M |
| Nov 12, 2024 |
10-Q filing | 60.1M shares outstanding |
60M | 53M |
| Aug 13, 2024 |
10-Q filing | 60.1M shares outstanding |
60M | 53M |
| May 14, 2024 |
10-Q filing | 59.8M shares outstanding |
60M | 53M |
| Mar 27, 2024 |
S-3 filing: This S-3 filing describes a shelf registration for the potential issuance of common stock, preferred stock, debt securities and/or warrants. |
60M | 53M |
| Mar 26, 2024 |
10-K filing | 60.1M shares outstanding |
60M | 53M |
| Nov 13, 2023 |
10-Q filing | 54.2M shares outstanding |
54M | 53M |
| Aug 08, 2023 |
10-Q filing | 57.9M shares outstanding |
58M | 53M |
| May 09, 2023 |
10-Q filing | 41.0M shares outstanding |
41M | 53M |
| Mar 27, 2023 |
10-K filing | 40.6M shares outstanding |
41M | 53M |
| Nov 14, 2022 |
10-Q filing | 40.5M shares outstanding |
41M | 53M |
| Aug 15, 2022 |
10-Q filing | 40.5M shares outstanding |
40M | 53M |
| Jul 01, 2022 |
S-3 filing: The company is filing an S-3 to offer and sell up to $200,000,000 of any combination of common stock, preferred stock, and debt securities, and may use the proceeds primarily for clinical trials, research and development, and working capital. |
40M | 53M |
| May 16, 2022 |
10-Q filing | 40.5M shares outstanding |
41M | 130K |
| Mar 28, 2022 |
10-K filing | 40.5M shares outstanding |
40M | 130K |
| Nov 15, 2021 |
10-Q filing | 40.5M shares outstanding |
40M | 130K |
| Aug 16, 2021 |
10-Q filing | 40.5M shares outstanding |
40M | 130K |
| Jun 24, 2021 |
S-1/A filing: This filing relates to the sale of unregistered securities by the company since January 2018, including issuances of common stock, convertible notes, and warrants. |
N/A | 130K |